The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), Johnson & Johnson (Gold), BeOne Medicines (Silver) and Lilly (Silver).
The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
General Updates | Fixed-duration versus continuous therapy in CLL: clinical considerations, the CLL17 trial, & more
In this discussion, Othman Al-Sawaf, MD, University Hospital of Cologne, Cologne, Germany, Lydia Scarfò, MD, Vita-Salute San Raffaele University & IRCCS San Raffaele Scientific Institute, Milan, Italy, and Alessandra Tedeschi, MD, Niguarda Cancer Center, Milan, Italy, explore key advances and clinical decision-making in chronic lymphocytic leukemia (CLL), focusing on the choice between continuous BTK inhibitor treatment and fixed-duration venetoclax-based regimens. They highlight how biomarkers such as TP53 status and patient characteristics guide treatment decisions, and summarize findings from the CLL17 trial (NCT04608318). The experts also address challenges in treatment sequencing and relapse management, commenting on emerging strategies, including MRD-guided therapy and novel combination regimens, as key areas for future optimization. This discussion took place virtually.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
